// App-Quantinova.ai

POS0689 (2021) : A 6-MONTH OPEN-LABEL EXTENSION STUDY OF THE SAFETY AND EFFICACY OF INTRAVENOUS BELIMUMAB IN PATIENTS WITH LUPUS NEPHRITIS

Researchers

Presenter

  • R. Furie

Principal Investigators

  • B. H. Rovin

  • F. Houssiau

  • G. Contreras

  • P. Curtis

  • A. Madan

  • A. Jones-Leone

  • M. Okily

  • D. Roth

Medical Centers

  • Northwell Health, Division of Rheumatology, Great Neck, United States of America

  • The Ohio State University, Division of Nephrology, Columbus, OH, United States of America

  • University of Miami Miller School of Medicine, Division of Cardiology, Department of Medicine, Miami, United States of America

  • GlaxoSmithKline, Department of Quantitative Sciences, Brentford, United Kingdom

  • GlaxoSmithKline, Global Medical Affairs, Collegeville, PA, United States of America

  • GlaxoSmithKline, Global Medical Affairs, Collegeville, PA, United States of America

  • GlaxoSmithKline, Immunoinflammation, Collegeville, PA, United States of America

  • GlaxoSmithKline, Global Medical Affairs, Collegeville, PA, United States of America

Locations

  • United States

  • Belgium

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

  • Nephrology

Disease

  • Lupus nephritis

Biomarkers

  • N/A

Drug/Treatment

  • Belimumab

Outcome

  • N/A

Study Design

  • Open Label

Phase

  • NA

Study Id's

  • NCT01639339

Sponsors

  • GlaxoSmithKline (GSK)

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved